Antigen News and Research

RSS
Sorrento, Karolinska Institutet partner to develop new NK cell-based therapies

Sorrento, Karolinska Institutet partner to develop new NK cell-based therapies

F-star signs agreement with AbbVie to discover, develop bispecific antibodies in immuno-oncology

F-star signs agreement with AbbVie to discover, develop bispecific antibodies in immuno-oncology

Virginia Tech scientists find potential way to influence memory formation in the immune system

Virginia Tech scientists find potential way to influence memory formation in the immune system

New project aims to develop CAR-T cell immuno-oncology cellular therapy for solid tumours

New project aims to develop CAR-T cell immuno-oncology cellular therapy for solid tumours

Men not having important discussions with health providers about prostate cancer screening, treatment

Men not having important discussions with health providers about prostate cancer screening, treatment

Study supports argument that declining PSA screening may lead to avoidable cancer deaths

Study supports argument that declining PSA screening may lead to avoidable cancer deaths

African American men with prostate cancer have significantly lower PSA density than Caucasian men

African American men with prostate cancer have significantly lower PSA density than Caucasian men

Immunogeneticist helps monitor immune responses in VRC01 phase 1 trial in HIV-infected individuals

Immunogeneticist helps monitor immune responses in VRC01 phase 1 trial in HIV-infected individuals

Shells of plant virus trigger immune system to wipe out tumors, provide protection against metastases

Shells of plant virus trigger immune system to wipe out tumors, provide protection against metastases

Univercells awarded grant to reduce cost of vaccine manufacturing in the Walloon region

Univercells awarded grant to reduce cost of vaccine manufacturing in the Walloon region

Adaptimmune begins Phase I/II study of affinity enhanced T-cell therapy targeting MAGE-A10 in NSCLC patients

Adaptimmune begins Phase I/II study of affinity enhanced T-cell therapy targeting MAGE-A10 in NSCLC patients

UCL Cancer Institute win $200,000 CytoFLEX Flow Cytometer from Beckman Coulter

UCL Cancer Institute win $200,000 CytoFLEX Flow Cytometer from Beckman Coulter

CRCHUM researchers find mechanism responsible for rejection of organ transplants

CRCHUM researchers find mechanism responsible for rejection of organ transplants

Simple diagnostic test can help fight deadly sleeping sickness

Simple diagnostic test can help fight deadly sleeping sickness

TSRI scientists track how HIV-fighting antibodies develop over time

TSRI scientists track how HIV-fighting antibodies develop over time

Exposure to farm animals, pets in early childhood modifies allergy-related immunological mechanisms

Exposure to farm animals, pets in early childhood modifies allergy-related immunological mechanisms

Study: Brain cell death may trigger multiple sclerosis

Study: Brain cell death may trigger multiple sclerosis

ImmunoCellular partners with CBTC for ICT-107 phase 3 registrational trial in patients with glioblastoma

ImmunoCellular partners with CBTC for ICT-107 phase 3 registrational trial in patients with glioblastoma

Repeating abnormal PSA tests can reduce unnecessary biopsies

Repeating abnormal PSA tests can reduce unnecessary biopsies

BioAtla, Pfizer sign license and option agreement for new class of antibody therapeutics

BioAtla, Pfizer sign license and option agreement for new class of antibody therapeutics

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.